Agios Pharmaceuticals(AGIO) - 2024 Q4 - Annual Results

Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Filed for Regulatory Approval of Mitapivat (PYRUKYND ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – ® – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expecte ...